Development and Application of a Humanized Lung Fibrosis Organoid Model with Stromal and Macrophage Niches for Pharmaceutical Evaluation

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background The preclinical development of therapies for pulmonary fibrosis (PF) faces a fundamental roadblock: existing models fail to simultaneously capture the complex multicellular pathophysiology of the human disease and provide a scalable platform for drug screening. This trade-off between physiological complexity and experimental scalability has severely hampered therapeutic progress. Methods To bridge this critical gap, we established a fully humanized in vitro platform by co-differentiating human induced pluripotent stem cells (hiPSCs) into lung organoids (hiLOs), functional fibroblasts (HF), and macrophages. This tri-culture system (hiLOFM) recapitulates the core functional units of the human lung-epithelium, stromal and immune components (macrophages) – within a controlled and reproducible microenvironment. Results Upon LPS and TGF-β1 challenge, the hiLOFM model robustly recapitulated hallmark fibrotic features, including myofibroblast activation (α-SMA, Fibronectin and Vimentin), extracellular matrix (ECM) deposition (Collagen I), and pro-inflammatory cytokines secretion (IL-11 and IL-1β). The integration of macrophages specifically amplified the fibrotic response, underscoring the critical role of stromal-immune crosstalk. The platform demonstrated high translational utility: it confirmed the efficacy of standard-of-care antifibrotics (pirfenidone and nintedanib), revealed a superior synergistic effect of their combination, and successfully identified the profibrotic toxicity of the anticancer agent DS-8201 at clinically relevant concentrations. Conclusions We present a human-based tri-culture system that effectively resolves the long-standing dilemma between complexity and scalability in PF modeling. This versatile platform provides a powerful and transformative tool for de-risking drug discovery by enabling simultaneous evaluation of efficacy and safety in a physiologically relevant context.

Article activity feed